. 2013 Oct 17;5(5):48. doi: 10.1186/alzrt213

Table 2.

First two therapeutic agents in the Dominantly Inherited Alzheimer Network trials unit

Drug	Type	Mechanism of action biomarker	Downstream biomarkers	Exploratory biomarkers
Solanezumab (Eli Lilly and Company)	Anti-Aβ antibody (soluble Aβ)	CSF total and free Aβ₄₀and Aβ₄₂	CSF tau, ptau181, vMRI	FDG-PET, fcMRI
Gantenerumab (Roche)	Anti-Aβ antibody (aggregated Aβ)	PET amyloid imaging	CSF tau, ptau181, vMRI	FDG-PET, fcMRI

Aβ, amyloid-beta; CSF, cerebrospinal fluid; fcMRI, functional connectivity magnetic resonance imaging; FDG-PET, fluorodeoxyglucose-positron emission tomography; PET, positron emission tomography; vMRI, volumetric magnetic resonance imaging.